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Background: Ensuring the quality of malaria medicines is crucial in working toward malaria control and eventual
elimination. Unlike other validated tests that can assess all critical quality attributes, which is the standard for
determining the quality of medicines, basic tests are significantly less expensive, faster, and require less skilled
labour; yet, these tests provide reproducible data and information on several critical quality attributes, such as
identity, purity, content, and disintegration. Visual and physical inspection also provides valuable information about
the manufacturing and the labelling of medicines, and in many cases this inspection is sufficient to detect
counterfeit medicines. The Promoting the Quality of Medicines (PQM) programme has provided technical assistance
to Amazon Malaria Initiative (AMI) countries to implement the use of basic tests as a key screening mechanism to
assess the quality of malaria medicines available to patients in decentralized regions.
Methods: Trained personnel from the National Malaria Control Programmes (NMCPs), often in collaboration with
country’s Official Medicine Control Laboratory (OMCL), developed country- specific protocols that encompassed
sampling methods, sample analysis, and data reporting. Sampling sites were selected based on malaria burden,
accessibility, and geographical location. Convenience sampling was performed and countries were recommended
to store the sampled medicines under conditions that did not compromise their quality. Basic analytical tests, such
as disintegration and thin layer chromatography (TLC), were performed utilizing a portable mini-laboratory.
Results: Results were originally presented at regional meetings in a non-standardized format that lacked relevant
medicines information. However, since 2008 information has been submitted utilizing a template specifically
developed by PQM for that purpose. From 2005 to 2010, the quality of 1,663 malaria medicines from seven AMI
countries was evaluated, mostly collected from the public sector, 1,445/1,663 (86.9%). Results indicate that 193/1,663
(11.6%) were found not to meet quality specifications. Most failures were reported during visual and physical
inspection, 142/1663 (8.5%), and most of these were due to expired medicines, 118/142 (83.1%). Samples failing TLC
accounted for 27/1,663 (1.6%) and those failing disintegration accounted for 24/1,663 (1.4%). Medicines quality
failures decreased significantly during the last two years.* Correspondence: vsp@usp.org
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the implementation of this type of quality monitoring programme in 2005. However, the lack of consistent
confirmatory tests in the quality control (QC) laboratory, utilizing methods that can also evaluate additional quality
attributes, could still mask quality issues. In the future, AMI countries should improve coordination with their health
authorities and their QC lab consistently, to provide a more complete picture of malaria medicines quality and
support the implementation of corrective actions. Facilities in the private and informal sectors also should be
included when these sectors constitute an important source of medicines used by malaria patients.Background
The quality of medicines is a global problem and one of par-
ticular concern in developing countries, where limited
human and financial resources may impair the implementa-
tion of appropriate quality assurance and quality control
(QA/QC) systems. The impact that this may have on medi-
cines utilized for the treatment of malaria, one of the major
endemic diseases in the world, could be severe. Poor quality
medicines have a detrimental effect on the lives of patients
by causing them to remain ill longer and spend more time
and financial resources obtaining treatment. They also can
undermine a country’s health care system, exhaust financial
and human resources, and exacerbate health problems, es-
pecially those associated with infectious disease, particularly
the development of resistance. Several reports attest to the
significance of this problem for malaria medicines in Africa
and Asia [1-12]. On the other hand, published data for mal-
aria medicines in the Americas is scarce [13,14].
In most countries, the institution responsible for ensuring
the quality of medicines is the national Medicines Regula-
tory Authority (MRA), which performs this task by imple-
menting Medicines Quality Monitoring (MQM) activities.
To support these activities, it is crucial that the MRA have
access to a laboratory that can properly perform QC ana-
lysis. Such testing is usually carried out by the Official Medi-
cine Control Laboratory (OMCL), particularly for medicines
used by Ministry of Health (MoH) programmes. All the
countries included in this study had an assigned OMCL.
The MQM activities described in this report took place in
the context of the Amazon Malaria Initiative (AMI) [15].
This initiative, established by the the United States Agency
for International Development (USAID), was launched in
2001; it utilizes a holistic approach with the overall goal of
preventing and controlling malaria and decreasing national
morbidity and mortality in the region. AMI currently
is implemented in seven countries in the Amazon Basin
(Bolivia, Brazil, Colombia, Ecuador, Guyana, Peru, and
Suriname) and selected countries in Central America; until
2008 Venezuela also participated in this initiative. AMI ac-
tivities are carried out by six technical international partners
with varied expertise, all of which work in close coordination
with each other and with national counterpart stakeholders.
The Promoting the Quality of Medicines (PQM) programme
[16], and its predecessor the Drug Quality and Information
(DQI) programme, implemented by the United StatesPharmacopeia (USP), has been involved in AMI since 2002,
providing technical assistance to ensure the quality of mal-
aria medicines.
Several of the indicators suggested in the Medicine
Quality Assessment Reporting Guidelines (MEDQUARG)
[17] were an integral part of the assessments and are
included in this report.
Quality control of malaria medicines in AMI countries
Initial assessments performed by PQM identified several
gaps associated with QA/QC systems in AMI countries:
(a) There was no information on the quality of malaria
medicines prior to distribution. Medicines in the public
sector were assumed to be of good quality because they
were distributed by the Ministry of Health; and although
malaria medicines were provided free of charge at public
health centres, patients could purchase malaria medicines
outside of the public sector; (b) Storage conditions at dif-
ferent levels of the distribution chain were deficient, pos-
ing the risk of affecting the quality of the medicines
administered to patients (see [14] and references within);
(c) The capabilities of most of the OMCLs to perform full
quality testing according to registration specifications was
seriously impaired by lack of finances, personnel and
equipment resources. In addition, most of the NMCPs in
AMI countries were vertical, operating independently of
the MRA and/or the OMCL. While addressing the
strengthening of QA/QC systems in a more systematic
manner, PQM recommended screening malaria medi-
cines in AMI countries utilizing the three-level approach
[18]. Each level in this approach consists of different
QC procedures, which increase in complexity and com-
plement the previous levels. Following is a brief descrip-
tion of each level:
Level 1 encompasses visual and physical inspection
(V&P) to assess the physical characteristics of the medi-
cines and compliance with specifications for two critical
quality attributes: packaging, and labelling. The latter
includes checking the expiration date and assessing the
package and/or insert for fraudulent, incorrect, and /or
deficient information. In addition, the physical inspection
of dosage forms may provide useful information about the
manufacturing processes (i.e., tablet preparations proce-
dures resulting in cracked, chipped or broken tablets).
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formed in the field. Currently, as implemented by PQM,
utilizes basic tests to evaluate four critical medicines
quality attributes - identity, content, impurities, and dis-
integration. Identity, content, and impurities are assessed
by Thin Layer Chromatography (TLC), comparing the
presence and intensity of spots with those of the corre-
sponding reference standards. Disintegration assesses the
capability of solid oral dosage forms (tablets and capsules)
to disperse in an aqueous environment within a preset
period of time. Although disintegration is not a proxy for
assessing dissolution, it is a prerequisite for proper dissol-
ution to occur. Dissolution, which requires a more sophisti-
cated methodology to be assessed, is the process required
in order for the active pharmaceutical ingredient (API) to
be dissolved and absorbed systemically.
Level 3 utilizes compendial tests or other validated
methods to assess all quality attributes according to
registration specifications. The critical attributes men-
tioned in Level 2 are evaluated typically with more
advanced analytical techniques such as high-perform-
ance liquid chromatography (HPLC) and dissolution.
While Level 1 and Level 2 may be assessed in the field
by specially trained personnel and with minimal sup-
plies, Level 3 requires skilled analysts and the infrastruc-
ture and equipment of an established laboratory.
According to PQM guidelines, Level 1 and Level 2
analysis are performed in the field on all samples, and
failed samples, as well as a subset of passing samples,
should be sent to the OMCL to perform Level 3 (con-
firmatory) testing. Alternatively, the OMCL may repeat
Level 2 on these samples (verification tests) before sub-
mitting all or some of them to Level 3 testing. However,
not all countries performed verification and/or con-
firmatory testing at the OMCLs; and in several countries
the follow-up by OMCLs to field testing was not per-
formed after every sampling round or at all sentinel
sites. Therefore, this report focuses only on the results
obtained by performing Level 1 and Level 2 testing by
field personnel at sampling sites.
Methods
The OMCL and field personnel from of each AMI coun-
try received training on sampling methodologies, perform-
ing V&P inspection and basic tests utilizing the Global
Pharma Health Fund (GPHF) MinilabW, a portable kit
containing the equipment, reference standards, and a
manual of procedures to perform basic tests [19]. The
manual provides TLC procedures for each medicine
included in the MinilabW. For disintegration, the protocol
requires tablets or capsules to be maintained in water for
30 minutes at room temperature and with occasional man-
ual swirling. Confirmatory testing (Level 3) was carried outat the OMCL. In Brazil Artesunate was analyzed according
to the International Pharmacopeia 4th edition, 2006; cloro-
quine, doxycycline, primaquine and quinine according to
the United States Pharmacopeia USP29-NF24, and meflo-
quine according to a method developed and validated by
the Faculdade de Farmácia, Universidade Federal de Minas
Gerais. In Guyana chloroquine and quinine samples were
analyzed according to the British Pharmacopiea BP 2010,
and mefloquine according to the corresponding USP non-
US monograph.
MQM activities were assumed in most countries by the
NMCP, which developed a country- specific protocol to
encompass sampling methods, sample analysis, and data
reporting. The sampling sites were chosen based on mal-
aria burden, accessibility, and geographical location. Sam-
pling was performed throughout the year, and frequency
varied amongst countries and within sites in each country.
Sample collection was performed using convenience sam-
pling, and countries were recommended to ensure proper
storage of the sampled medicines to avoid compromising
their quality after collection (e.g. maintaining samples in
their original sealed containers according to the storage
instructions for the respective product; packaging with
suitable material to protect their integrity during transpor-
tation; ensuring correct sealing of containers; etc). Most
medicines were sampled from the public sector (e.g.,
malaria diagnostic and treatment centers, hospitals), and
seldom from the private sector (facilities with a license
to sell medicines, e.g., pharmacies, retail stores) or the
informal sector (facilities without a license to sell medi-
cines, e.g., street markets, convenience stores, ambula-
tory vendors). In AMI countries, malaria medicines are
usually procured centrally by the NMCP or other de-
pendency within the MoH, and subsequently distributed
to decentralized areas; modalities in these processes
vary from country to country [20].
A sample was considered “failed” if it did not comply
with V&P inspection and/or basic tests requirements,
when performed as described above under Level 1 and
Level 2. PQM recommends performing V&P inspection
and basic tests on all samples except for expired medi-
cines; however all expired medicines sampled in Bolivia
and Colombia were also submitted to quality control
testing. Samples were considered failed if they did not
pass either basic test, disintegration or TLC; when failing
one of them it was not submitted to the other.
Results
This paper reports the QC results of malaria medicines
sampled from 2005 to 2010 in AMI countries. All AMI
countries have now adopted the use of basic tests as part
of MQM at sentinel sites. However, due to logistic issues
related in part to the management of certain reagents,
Peru experienced delays in its implementation, and no
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try-specific reports were initially developed by the
NMCPs and, until 2007, the reporting format varied
from country to country. Subsequently, PQM developed
a uniform reporting format that was adopted by the
countries and has been utilized since 2008.
Sector of medicines sampled
The majority of the data reported by the NMCPs comes
from medicines sampled in the public sector (1,445/1,663,
86.9%), as indicated in Table 1, with the private sector
accounting for 152/1,663 (9.1%) and the informal sector
for only 27/1,663 (1.6%). Most of the medicines sampled
in the informal sector were from Guyana (13/27, 48.1%)Table 1 Country medicines sampled by sector
Country Year Total Sampled
Publi




Bolivia Total 306 296 (96.
Brazil 2006 32 28
2007 187 179
2008 94 94
Brazil Total 313 301 (96.





Colombia Total 557 504 (90.
Ecuador 2005 43 24
2006 59 26
2007 7 1
Ecuador Total 109 51 (46.8




Guyana Total 289 220 (76.
Suriname 2007 20 4
Suriname Total 20 4 (20%
Venezuela 2006 12 12
2007 57 57
Venezuela Total 69 69 (100.
Total 1663 1445 (86and Suriname (11/27, 40.7%,), where malaria is endemic
in the mining areas and public sector facilities are scarce
and difficult to access. The informal sector is also known
to exist in other countries, but no results from medicines
in this sector were reported. The information of the
sources of about 39/1,663 (2.3%) of the sampled medicines
is unknown, because initial reports from certain countries
did not identify the sector from which the medicines were
sampled, particularly Ecuador (19/59, 32.2%,) in 2006 and
Guyana (18/72, 25.0%,) in 2008.
Quality control results
Table 2 summarizes the findings of V&P inspection and
basic tests results reported by AMI countries. Except forSector
























1%) 38 (13.1%) 13 (4.5%) 18 (6.2%)
5 11 0
) 5 (25%) 11 (55%) 0
0 0 0
0 0 0
0%) 0 0 0
.9%) 152 (9.1%) 27 (1.6%) 39 (2.3%)
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100 samples per country were submitted and since 2008
most indicated a significant decrease in the percentage
that did not pass QC testing (failures). Of the results sub-
mitted, 193/1,663 (11.6%) of the medicines were classified
as failing.
It is worth noting that from the 11.6% total failure
rate, 8.5% (142/1663, 8.5%) was due to failure in V&P in-
spection. This trend, in which the majority of failures
are due to V&P inspection, was observed in four of the








Bolivia Total 306 58 (19.0%) 56
Brazil3 2006 32 7
2007 187 12
2008 94 1
Brazil Total 313 20 (6.4%) 6





Colombia Total 557 46 (8.3%) 39
Ecuador 2005 43 11
2006 59 7
2007 7 0
Ecuador Total 109 18 (16.5%) 12




Guyana Total 289 21 (7.3%) 8
Suriname 2007 20 0
Suriname Total 20 0
Venezuela 2006 12 4
2007 57 26
Venezuela Total 69 30 (43.5%) 21
Total 1663 193 (11.6%) 14
V&P = visual and physical inspection; TLC = thin-layer chromatography.
1 In the V&P columns, the first represent total failures, including expired samples, a
2 All expired samples were submitted to quality control testing.
3 For doxycycline, (Brazil) and dihydroartemisinin or piperaquine (Suriname), there w
assessed.all the samples failing V&P inspection in Bolivia (56),
Brazil (6), and Guyana (8) failed because they were
expired when collected, as did most of the samples in
Colombia (30/39) and Ecuador (10/12).
Overall, expired medicines accounted for 118/142
(83.1%) of the samples that failed V&P inspection. The
two countries experiencing the highest rate of expired
products (Bolivia in 2006 and 2007, and Colombia in
2008) addressed this problem by better controlling their
inventory, and in subsequent years no expired medicines
were reported.sts by country
Failed V & P Inspection1 Failed Basic Tests
Total Expired Disintegration TLC
37 37 0 0
19 19 2 0
0 0 0 0
0 0 0 0
(18.3%) 56 (18.3%) 2 (0.7%) 0
4 4 0 3
1 1 0 11
1 1 0 0
(1.9%) 6 (1.9%) 0 14 (4.5%)
0 0 0 0
10 1 7 0
29 29 0 0
0 0 0 0
0 0 0 0
(7.0%) 30 (5.4%) 7 (1.3%) 0
6 4 1 4
6 6 1 0
0 0 0 0
(11.0%) 10 (9.2%) 2 (1.8%) 4 (3.7%)
0 0 1 0
6 6 12 0
1 1 0 0
1 1 0 0
(2.8%) 8 (2.8%) 13 (4.5%) 0
0 0 0 0
0 0 0 0
4 0 0 0
17 8 0 9 (13.0%)
(30.4%) 8 (11.6%) 0 9 (13.0%)
2 (8.5%) 118 (7.1) 24 (1.4%) 27 (1.6%)
nd the second only expired samples.
as no validated TLC method available at the time and only disintegration was
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spection failures were not due to expired medicines were
Colombia in 2007 and Venezuela in 2006 and 2007. In
Colombia, most of these failures were due to damaged
packages, in which blisters were not tightly sealed or the
legend was illegible. In Venezuela, sampled medicines
were not in the original package and lacked information
on their source, lot number and/or expirations dates;
also in Venezuela V&P inspection identified samples
containing irregularly shaped, chipped or broken tablets.
Disintegration was the least failed basic test with 24
failures (1.4%), a few more samples, 27 (1.6%), failed
TLC. In four countries (Bolivia, Colombia, Ecuador, and
Venezuela) V&P inspection accounted for the majority
of failures; in Brazil and Guyana failures in basic tests were
more prominent. A single medicine accounted for all the
failures in basic tests in Colombia (seven sulphadoxine-
pyrimethamine samples), Guyana (13 chloroquine samples)
and Brazil (14 quinine samples).
Following is a brief summary of findings per country
that includes the type of medicines failing basic tests:
Bolivia. Data for a total of 306 samples were submit-
ted from Bolivia between 2006 and 2009. Most failures
(56/58) were due to expired medicines; however, in
subsequent years, as mentioned above, no expired med-
icines were identified. The only failures in basic tests
detected in Bolivia (2007) were 2/30 (6.7%) chloroquine
samples that did not pass disintegration test. Even
though PQM recommended not to submit expired
samples to quality control testing, the large number of
expired samples were analyzed; no failures were
detected amongst those.
Brazil. Data for a total of 313 samples were submitted
from Brazil between 2006 and 2008. The 14 failures in
basic tests were sampled that failed the TLC test, with
quinine accounting for 3/5 (60.0%) in 2006, and 11/41
(26.8%) in 2007. Seven quinine samples that failed TLC
were subsequently analysed at the reference laboratory
and passed compendial (confirmatory) testing; however,
only field results are included in Table 2. After 2008,
Brazil NMCP discontinued the use of basic tests for the
assessment of malaria medicines quality, while evaluat-
ing alternative processes to perform QC of malaria
medicines.
Colombia. Data for a total of 557 samples were submit-
ted from Colombia between 2006 and 2010. The number
of failed medicines decreased significantly during the last
two years assessed, with no failures reported in 2009 and
2010. The overall failure rate was 8.3% (46/557), mostly due
to V&P inspection (39/46), of which 30 samples were
expired medicines. In Table 2, among all the samples that
failed in 2007, 7/23 (30.4%), were sulphadoxine-pyrimeth-
amine containing medicines that failed disintegration. Even
though PQM recommended not to submit expired samplesto quality control testing, the large number of expired sam-
ples were analyzed, but no failures were detected.
Ecuador. Data for a total of 109 samples were submit-
ted from Ecuador between 2005 and 2009. No reports
were received for 2007 and 2008. The data indicates a
drop in the failure rate over time as well. All the failures
were found in 2005 (n: 11) and 2006 (n: 7); 10 of 12
samples failing V& P inspection were expired medicines.
In 2005, 4/11 (36.4%) primaquine samples failed TLC
and 1/8 (12.5%) sulphadoxine-pyrimethamine containing
medicine failed disintegration. In 2006, 1/2 (50.0%) quin-
ine sample failed disintegration.
Guyana. Data for a total of 289 samples were submit-
ted from Guyana between 2007 and 2010. Of the 21
samples that failed over four years, 18 were identified in
2008. All those failing V&P inspection (n: 8) were
expired medicines, while 1/14 (7.1%) and 12/12 (100%)
chloroquine samples failed disintegration in 2007 and
2008 respectively.
Suriname. Data was submitted from Suriname only in
2007, and it comprises 20 samples. From these, one sam-
ple contained dihydroartemisinin and 11 consisted of
ArtecomW, a fixed-dose combination (FDC) therapy
reported to contain dihydroartemisinin, piperaquine and
trimethoprim, for which there was no basic test available
at the time. No information was provided on whether
the blisters with the FDC in the ArtecomW samples con-
tained also a single primaquine tablet (see below).
The results in Table 2 reflect only the disintegration
test assessed for those 12 samples. Based on this and
the small number of medicines collected, no definite
conclusion may be drawn from this country data. It is
worth noting that a FDC with the same brand name
(ArtecomW) was the most prevalent malaria medicine
identified in a recent study performed in the private
and informal market in Guyana and Suriname, in
which each blister in the package contained a single
primaquine tablet [21]. All the samples of this medi-
cine in the mentioned studies failed V&P inspection
because there was no content information on the
dose of the primaquine tablet in the package or the
insert.
Venezuela. A total of 69 medicines were reported by
Venezuela, in 2006 and 2007, with a failure rate of 43.5%
(30/69). However, as was the case of other countries,
most of these failures were due to V&P inspection (21/
30, 70%). During 2007 TLC failures were found in 4/17
(23.5%) cloroquine samples, 2/13 (15.4%) mefloquine
samples and 3/24 (12.5%) primaquine samples. Vene-
zuela ceased participating in AMI activities in 2008.
Table 3 provides information according to the API of the
sampled medicines, which supplements the data detailed
above for the medicines that failed in each country.
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most often sampled and analysed medicines representing
54.2% of the total, while artesunate and other medicines
containing artemisinin-derivatives accounted for 19.2% (n:
320). Taking into account that the majority of medicines
were sampled in the public sector, the larger numbers for
chloroquine and primaquine probably reflect the fact that
Plasmodium vivax is the prevalent malaria infection found
in the region, and these two medicines are included in the
national and World Health Organization (WHO) guidelines
for its treatment [22]. It is important to note, that all the
failures for artemisinin-derivative medicines (n: 22) were
due to V&P inspection. Medicines containing sulphadox-
ine-pyrimethamine had the highest rate of failure at 20.9%
(14/67), of which six failed V&P inspection and eight
failed disintegration. It is interesting to note that dissol-
ution was the most common reason for sulphadoxine- pyri-
methamine failures reported in other studies [7,8,23,24].
Whether in this case there was any correlation between
these two quality attributes cannot be assessed because of
the lack of confirmatory testing for dissolution at the la-
boratory. Table 4 shows results from a subset of samples
that underwent both basic and confirmatory testing in Bra-
zil and Guyana. The data attests to the importance of per-
forming confirmatory testing on subsets of the samples,
including a percentage of those that pass basic tests. In Bra-
zil, 7 quinine samples that failed basic tests were found
to be compliant by confirmatory tests. It is worth noting
that in Brazil, 3 other quinine samples with the same lot
number of those included in Table 4, were collected atTable 3 Test Results by API in Medicine
Active Pharmaceutical Ingredientq Failures
Amodiaquine 1/49 (2.0%)
Artemether1 2/10 (20.0%)




Dihydroartemisinin-Piperaquine- Trimethoprim2 0/11 (0%)






1 Artemisinin derivatives containing medicines and doxycycline samples failed
only V&P Inspection.
2 For medicines containing doxycycline, in Brazil, and dihydroartemisinin or
piperaquine, in Suriname, there was no validated TLC method available at the
time; therefore, only disintegration was assessed. Subsets of doxycycline
samples sent to the reference laboratory in Brazil passed validated tests for
identification and content.another sentinel site and passed both basic test and con-
firmatory testing (data not shown). On the other hand,
in Guyana, five samples (one chloroquine and four quin-
ine) that passed TLC, failed the confirmatory testing for
content of API. The compendial method that assesses
content revealed that those five samples were outside the
label specifications; though those differences were too
small to be detected through TLC.
Discussion
The overall failure rate found for samples collected
during the 2005–2010 survey (11.6%) is significantly
lower than that reported in other regions of the world
[1-10]. It is important to keep in mind that the scope
of most of the other studies, the number of medicines
collected, the sectors from which the medicines were
sampled, and the methodologies utilized were different;
all of which precludes drawing major conclusions from
a comparison of overall failures rates. Among those
studies, two of those performed in Africa [7,8] merit
particular attention because both basic tests and com-
pendial tests were utilized to assess subsets of the
sampled medicines.
The followings sections describe positive outcomes
from the implementation of basic QC tests by NMCPs
in AMI countries:
Unique regional QC approach in Latin America and the
Caribbean (LAC)
Despite the differences in their QA/QC systems, the
approach discussed in this paper was embraced by all
participating AMI countries; this allowed regionalTable 4 Comparison of Basic and Confirmatory Test
Results
Country API1 Basic Tests Confirmatory Testing
for Content2
Pass Fail Pass Fail
Brazil Artesunate 1 0 1 0
Chloroquine 1 0 1 0
Doxycycline3 2 0 2 0
Mefloquine 1 0 1 0
Primaquine 5 0 5 0
Quinine 0 7 7 0
Guyana Chloroquine 13 0 3 1
Mefloquine 1 0 1 0
Quinine 14 0 1 4
Total 38 7 22 5
1 Medicines collected during one round of sampling at one sentinel site in
each country.
2 All samples passed the identity test.
3 There was no validated TLC method available.
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the years and provided the first documented regional
information on the quality of malaria medicines. There
is no other programme in LAC pursuing a regional ap-
proach to QC for other endemic diseases, including
other vector-borne diseases.Feasibility to perform QC of medicines in remote areas
In certain countries, the incidence of malaria is most
prevalent in remote areas where access is difficult due to
geographical barriers and the cost associated with trans-
port; particularly in gold mining areas in Brazil, Guyana
and Suriname. Storage conditions in these regions are
frequently deficient and public services are difficult to
access; therefore there is a high risk of medicines deteri-
orating (see [14] and references within) and also of
patients accessing medicines of questionable quality in
the informal sector. Through this approach, data on the
quality of medicines available to patients in these remote
areas was gathered for the first time.Improvement in the quality of malaria medicines
Overall, the results of this report clearly indicate that the
rate of malaria medicines failures in AMI countries com-
pares favorably with other regions of the world and these
failures have decreased significantly in recent years, at
least in the public sector. The very small number of fail-
ures identified during the last two years (see Table 2)
contrast dramatically with the results of the studies per-
formed in Africa [7,8], in which sampling was performed
just one year before.
The following aspects are worth highlighting:
a. The majority of failures were due to V&P inspec-
tion, most of which were expired medicines; their num-
ber decreased dramatically in all countries after 2008.
Medicines’ shelf life is based on manufacturer’s stability
studies, which ensure that medicines properly stored
during the period of validity maintain their quality attri-
butes. Medicines that are of good quality when procured
may degrade and become of poor quality if not stored
properly (see [14] and references within) or if stored be-
yond their expiry date. If expired medicines are analyzed
and found non-compliant with their quality specifica-
tions, it could be more difficult to implement the proper
corrective action with the manufacturer because degrad-
ation of an otherwise good quality medicine could be
the cause. See [17] and references within for definitions
and distinctions between counterfeit, substandard and
degraded products. Based on V&P inspection or basic
tests results it was not obvious that the poor quality
medicines identified were counterfeits. With the type of
failures identified, determining whether they were due to
counterfeits would have required confirmatory and/orother forensic testing and follow up with the manufacturer.
b. Medicines containing artemisinin derivatives failed
“only” V&P inspection. In contrast, the two recent stud-
ies in Africa [7,8] identified failures in artemisinin-con-
taining medicines in samples submitted to both basic
tests and undergoing compendial testing. Poor quality
artemisinin derivatives could be a factor in generating
resistance to a family of drugs that has no replacement
in the foreseeable future for the treatment of falciparum
malaria. This is of particular relevance because of recent
reports suggesting a rise in resistance to artemisinine
derivatives in vivo and in vitro in southeast Asia [25,26],
a region in which poor quality samples of these products
have been identified. MQM activities in AMI countries
using basic tests as a screening methodology also faced
three main challenges, described in more detail below.Lack of verification/confirmatory testing at the laboratory
of samples tested in the field
A critical component of conducting MQM activities util-
izing the three-level approach is to perform verification
tests (repetition of basic tests) and/or confirmatory tests
(testing according to compendial or other validated
methods utilized for registration) at the OMCL, on sub-
sets of the samples tested in the field. However, since a
very limited number of samples underwent these tests,
caution needs to be exerted when drawing conclusions
on the overall rate of failures reported utilizing basic
tests in the field.
The cases of the mefloquine and quinine samples in
Guyana that passed basic tests in the field but failed at
the OMCL, and the quinine samples in Brazil, which
failed in the field but passed at the reference labora-
tory, attests to the need of support from a laboratory
(see Table 4). The more sensitive methods utilized to
assess content allows for the detection of small differ-
ences in the levels of APIs and presence of impur-
ities. The different results on the quinine samples
from Brazil that failed at one site and were compliant
at another highlight the convenience of the laboratory
performing occassionally verification (basic) tests to
assess the proficiency of field personnel.
The additional information that compendial testing
can provide, also in subsets of samples passing basic
tests, is further exemplified in the two studies per-
formed in Africa [7,8]. In those, the results for samples
submitted to basic and/or compendial testing showed
a significantly higher rate of failures in the latter. This
tendency was due in part to the type of analysis (disin-
tegration vs. dissolution) and the sensitivity of the
methodology (particularly in the case of impurities for
artemisinin derivatives).
Pribluda et al. Malaria Journal 2012, 11:202 Page 9 of 11
http://www.malariajournal.com/content/11/1/202Not performing verification and/or confirmatory test-
ing as a regular practice has been the primary deficiency
in the management of MQM activities by NMCPs in
most AMI countries. Although timely delivery of results
by the lab was a problem, more often than not, the pri-
mary issue was the lack of coordination between
NMCPs, MRAs and OMCLs while performing MQM
activities at sentinel sites.
Sampling primarily from the public sector
Most medicines tested were sampled in the public sector
(86.9%). As a result, the current MQM data may not ne-
cessarily reflect the entire market available to patients,
particularly in areas where malaria medicines are pur-
chased in the private and informal sectors due to scar-
city of public sector facilities and/or difficulties in
accessing those facilities. Recent case studies performed
in the private and informal sectors in Guyana and
Suriname [21], where the percentage of failed samples
was significantly higher than those reported in this art-
icle confirm this assumption. However, in those case
studies medicines were analysed by compendial meth-
ods, and the higher percentage of failed samples partially
reflects this fact. In addition, in both countries all Arte-
comW samples failed because of the reasons detailed
under Suriname in the Results section. Similarly, in one
of the recent studies performed in Africa [7], the failure
rates in the private and informal sectors were 1.8 and
2.5 higher than in the public sector.
Inability to test all available malaria medicines due to the
lack of basic tests procedures
Doxycycline medicines in Brazil and more than 50% of
the samples (ArtecomW) from Suriname could not be
assessed by TLC due to the lack, at the time, of a vali-
dated TLC methodology.
General considerations on the use of basic tests
Basic tests offer a consistent, rapid, and cost-effective
means for monitoring medicines quality in the field. Those
are of the utmost importance for these countries’ needs.
(a) In endemic areas, where medicines are in constant
demand but storage conditions are frequently deficient,
it enables constant surveillance in a timely manner. (b)
Many endemic areas, such as gold mining regions in
Brazil, Guyana and Suriname, are very difficult to access.
The minimal equipment and materials required for basic
tests enables them to be performed in situ, obviating the
needs of time consuming, often expensive and difficult
shipment to the OMCL. (c) In many AMI countries,
local health offices in decentralized areas usually operate
under stringent budgets that limit both the personnel
available to perform tests and the availability of costlyreagents and equipment; the use of basic tests provides a
cost-effective means to address these circumstances.
It is very important, however, to also take into account
the limitations of this approach:
(a) The Guyana 2010 results show that basic tests, spe-
cifically TLC, found fewer failures than the confirmatory
tests used to analyse the same medicines. The assay
value obtained for chloroquine with the TLC confirma-
tory test was 90.0%, just outside the range (93.0% to
107.0%) of the HPLC confirmatory test method. The
four quinine medicines that failed the HPLC confirma-
tory testing did so by having averages ranging from
106.3% to 111.5%. The fractional differences found at
the OMCL could hardly be detected using the semi-
quantitative visual assessment of the intensity of the
TLC spots. In addition, visual detection of spots in TLC
is subjective and may also lack the sensitivity to identify
certain impurities; a problem frequently encountered for
artemisinin derivatives. Even if small deviations are
detected with basic tests, it is necessary to perform con-
firmatory testing; but proper judgement needs to be
exerted on their use when urgent treatement is required.
(b) The Brazil 2007 results for the quinine samples
that failed TLC testing, uncover another limitation of
basic tests performed in the field: poor field conditions
or poorly trained personnel. The tests performed on the
same medicines at the lab indicated that those samples
passed compendial testing, supporting the recommenda-
tion of sending all failed samples for verification and/or
confirmatory testing.
(c) Despite the fact that poor disintegration could im-
pact negatively on the dissolution rate, it is important to
reiterate that disintegration is not a proxy for dissol-
ution. This must be taken into account even when con-
sidering that all the sulphadoxine-pyrimethamine that
failed basic tests, 57.1% (8/14) failed disintegration,
though dissolution has been a common problem for sul-
phadoxine-pyrimethamine in other studies [6,7,16,17].
Regardless of the benefits that basic tests offer, it is
equally important to understand their limitations, a
conclusion also drawn from the recent studies in Africa
[7,8]. These limitations need to be considered when
comparing basic tests with compendial testing for
certain quality attributes, such as dissolution and
impurities [7,8] or with more elaborated methodologies,
such as Raman and/or near-infrared spectrometry
[27,28]. The limitations, on the other hand, emphasize
the need of utilizing basic tests in a context of periodic
assessment also by compendial methods.
Conclusions
According to V&P inspection and basic test results, the
quality of malaria medicines in AMI, primarily in the
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mentation of this type of assessment in 2005. Most failures
were due to medicines that did not pass V&P inspection,
and the majority of those were expired medicines. Only 3%
of the samples failed basic analytical tests, which compares
very favorably with results obtained recently in Africa and
Southeast Asia. However, AMI countries need to perform
confirmatory testing more consistently in order to
strengthen their quality assurance systems for malaria
medicines. Due to the lack of confirmatory testing, quality
issues such as dissolution and/or impurities may have
passed unnoticed and/or may still persist.
The benefits of periodic and systematic assessment as
a diagnostic tool in the supply chain is well exemplified
in the results of the two countries showing the greatest
number of expired medicines in early years, which was
subsequently corrected.
There is also a need to assess more frequently the pri-
vate and informal sectors, particularly in areas where
patients do not have access to the medicines distributed
by the NMCP. Having evidence on the availability of
malaria medicines in these sectors and their quality will
help health authorities implement the appropriate cor-
rective actions.
A better coordination of NMCP activities with MRAs
and OMCLs needs to be implemented. This will allow
not only the withdrawal of failed medicines from storage
facilities and/or points of use, but also implementation
of proper follow-up on the root cause of the problem
along the supply chain, whether it be due to poor QA/
QC during procurement, manufacturers not complying
with GMP, deficiencies in distribution practices, or poor
management of inventories. The implementation of V&P
inspection and basic tests by NMCP provided much
needed data on the quality of malaria medicines in AMI
countries, mostly in the public sector. Although this has
been a very important first step in ensuring that patients
receive quality-assured medicines, there is room for im-
provement in this process, mainly by the involvement of
all the relevant stakeholders.Abbreviations
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